Even though disabling p53 mutations occur in a third of non-aflatoxin-induced HCC [51], the oncogenic pathway driven by SOCS3-p53-CDKN1A axis could still occur in a considerable proportion of HCC cases with low SOCS1 and intact SOCS3 expression. This evidence concerns the gene CDKN1A and hepatocellular carcinoma.